Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical significance of concurrent TP53 mutations in KRAS-mutant invasive mucinous adenocarcinoma patients undergoing curative-intent lung surgery.

Cancer treatment and research communications - 1 Jan 2025

Yoon Dong Woog, Hwang Soohyun, Lee Boram, Jeon Yeong Jeong, Lee Junghee, Shin Dong Wook, Jeong Byeong-Ho, Park Seong Yong, Kim Hong Kwan, Choi Yong Soo, Cho Jong Ho

Abstract excerpt

BACKGROUND: Invasive mucinous adenocarcinoma (IMA) is genetically distinct from non-mucinous adenocarcinoma, commonly characterized by KRAS mutations. However, studies exploring molecular co-alterations alongside KRAS mutations in IMA remain limited. METHODS: We reviewed 84 patients with surgically resected IMAs from 2015 to 2023 who underwent NGS using TruSight™ Oncology 500 or CancerSCAN assays. Overall...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Mucinous
Share to Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Clinical Relevance

Share to Lung Neoplasms

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 41101001
DOI: 10.1016/j.ctarc.2025.101014

Genes

KRAS
TP53
CDKN2A
ERBB2
PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 15 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical significance of concurrent TP53 mutations in KRAS-mutant invasive mucinous adenocarcinoma patients undergoing curative-intent lung surgery.PMID 41101001Read ↗

Prognostic Impact of KRAS-TP53 Co-Mutations in Patients with Early-Stage Non-Small Cell Lung Cancer: A One Institution Retrospective AnalysisSemantic proximity Read ↗

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.Semantic proximity Read ↗

EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.Semantic proximity Read ↗

KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.Semantic proximity Read ↗

Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes.Semantic proximity Read ↗

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Semantic proximity Read ↗

Cancer-Type Specific Prognostic Impact of Concurrent TP53 and KRAS Alterations: A Multi-Cohort Genomic AnalysisSemantic proximity Read ↗

The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

Comparison of the immunotherapy efficacy between invasive mucinous and non-mucinous adenocarcinoma in advanced lung cancer patients with KRAS mutation: a retrospective study.Semantic proximity Read ↗

A Pan-Cancer Assessment of RB1/TP53 Co-MutationsSemantic proximity Read ↗

TP53 co-mutations are associated with elevated PD-L1 expression and high tumor mutational burden in non-small cell lung cancer: insights from comprehensive genomic profilingSemantic proximity Read ↗

Co-occurring genomic alterations and immunotherapy efficacy in NSCLCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.